Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines
Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , we...
Saved in:
Published in | Cancer cell international Vol. 14; no. 1; p. 68 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
24.10.2014
BioMed Central Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 1475-2867 1475-2867 |
DOI | 10.1186/1475-2867-14-68 |
Cover
Abstract | Background
Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from
Garcinia hanburyi
, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.
Methods
KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.
Results
Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.
Conclusion
The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for
Opisthorchis viverrini
(OV)-associated CCA. |
---|---|
AbstractList | Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.BACKGROUNDChemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines.KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.METHODSKKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis.Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.RESULTSIsomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups.The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA.CONCLUSIONThe combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA. BACKGROUND: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. METHODS: KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. RESULTS: Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. CONCLUSION: The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA. Doc number: 68 Abstract Background: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. Methods: KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Results: Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. Conclusion: The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA. Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi, were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA. Background Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds represent a promising strategy. In our previous studies, isomorellin and forbesione, caged xanthones isolated from Garcinia hanburyi , were found to induce cell cycle arrest and apoptosis in CCA cell lines. The subject of our inquiry is the synergistic effect(s) of these caged xanthones with doxorubicin on growth inhibition and apoptosis induction in human CCA cell lines. Methods KKU-100, KKU-M139 and KKU-M156 cell lines and Chang cells were treated with either isomorellin or forbesione alone or in combination with doxorubicin. Cell viability was determined using the sulforhodamine B assay. The combined effects of plant compounds with doxorubicin were analyzed using the isobologram and combination index method of Chou-Talalay. Apoptosis was determined by ethidium bromide/acridine orange staining. Protein expressions were determined by Western blot analysis. Results Isomorellin or forbesione alone inhibited the growth of these CCA cell lines in a dose-dependent manner and showed selective cytotoxicity against CCA cells but not against Chang cells. Isomorellin/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-M139 and KKU-M156 cells, while the forbesione/doxorubicin combination showed a synergistic growth inhibitory effect on KKU-100 and KKU-M139 cells. The percentages of apoptotic cells were significantly higher in the combined treatments than in the respective single drug treatments. The combined treatments strongly enhanced the expression of Bax/Bcl-2, activated caspase-9 and caspase-3, while suppressing the expression of survivin, procaspase-9 and procaspase-3, compared with single drug treatments. The degree of suppression of NF-κB activation mediated by a decrease in the expression of NF-κB/p65, a reduction of the pIκB-α level and an increase in the IκB-α protein level, was significantly higher in the combined treatment groups than in the single drug treatment groups. The degree of suppression of MRP1 protein expression was also significantly higher in the combined treatment than in the single drug treatment groups. Conclusion The combinations of isomorellin/doxorubicin and forbesione/doxorubicin showed significant synergistic effects on the growth inhibition and apoptosis induction in KKU-M156 and KKU-100 cells. Caged xanthones may be useful adjunct treatments with chemotherapy for Opisthorchis viverrini (OV)-associated CCA. |
Author | Kanthawong, Sakawrat Hahnvajanawong, Chariya Reutrakul, Vichai Chomvarin, Chariya Wattanawongdon, Wareeporn Sripa, Banchob Anantachoke, Natthinee |
Author_xml | – sequence: 1 givenname: Chariya surname: Hahnvajanawong fullname: Hahnvajanawong, Chariya email: hchari@kku.ac.th organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University – sequence: 2 givenname: Wareeporn surname: Wattanawongdon fullname: Wattanawongdon, Wareeporn organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University – sequence: 3 givenname: Chariya surname: Chomvarin fullname: Chomvarin, Chariya organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University, Liver Fluke and Cholangiocarcinoma Research Center, Khon Kaen University – sequence: 4 givenname: Natthinee surname: Anantachoke fullname: Anantachoke, Natthinee organization: Department of Pharmacognosy, Faculty of Pharmacy, Mahidol University – sequence: 5 givenname: Sakawrat surname: Kanthawong fullname: Kanthawong, Sakawrat organization: Department of Microbiology, Center of Excellence for Innovation in Chemistry, Faculty of Medicine, Khon Kaen University – sequence: 6 givenname: Banchob surname: Sripa fullname: Sripa, Banchob organization: Department of Pathology, Faculty of Medicine, Khon Kaen University – sequence: 7 givenname: Vichai surname: Reutrakul fullname: Reutrakul, Vichai organization: Department of Chemistry, Faculty of Science, Mahidol University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25866479$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1v1DAQhi1URD_gzA1Z4sIl1PY6tnNBgoovqRIH4Gw5jrPrKvEsdlLojZ_ORNtW24o9eex55vXrGZ-SowQpEPKSs7ecG3XOpa4rYZSuuKyUeUJO7k-O9uJjclrKFWNcG8WekWNRG6Wkbk7I3-83KeR1LFP0NPR98FOh0NNYYIQchiEm6lJHe8htKBFvp7_jtKEd_IE8t9FjHhDZwnaCEguNqZv9hCBGdDOPLlG_gcGldQTvMvIwOupRmaJ2KM_J094NJby4Xc_Iz08ff1x8qS6_ff568f6yapUQUxUapjtWM-l445XomRCd16yRK6NlrXBfa4n5TgVpZNO7TvOGe9GpxgXWy9UZebfT3c7tGDof0pTdYLc5ji7fWHDRPsykuLFruLZy1QijDQp82Am0EQ4IPMx4GO0yAbtMACOrFpE3ty4y_JpDmewYy9IMlwLMxXKlV0ybWtSIvn6EXsGcE_YIKSGaWhnDkHq1_6x7O3cTRqDeAT5DKTn01sfJLQNCk3GwnNnlJ_3H6fmjujvpwxVsV1GQTOuQ9wwfKPkHCpDcYA |
CitedBy_id | crossref_primary_10_3389_fonc_2022_850732 crossref_primary_10_3390_app15031125 crossref_primary_10_3390_cells9020498 crossref_primary_10_3389_fonc_2022_834072 crossref_primary_10_1016_j_biopha_2022_113610 crossref_primary_10_1016_j_jconrel_2020_02_018 crossref_primary_10_1021_acs_jnatprod_9b00018 crossref_primary_10_15212_AMM_2022_0001 crossref_primary_10_2174_0113816128286282240405064210 crossref_primary_10_1016_j_clinre_2017_12_006 crossref_primary_10_1152_ajpcell_00176_2024 crossref_primary_10_1055_a_1676_9678 crossref_primary_10_1177_1534735420911430 crossref_primary_10_1007_s13596_017_0278_6 crossref_primary_10_3892_ol_2016_5284 crossref_primary_10_1016_j_bbadis_2017_06_005 crossref_primary_10_1039_D1FO03542H |
Cites_doi | 10.1016/S0968-0004(00)01617-0 10.1016/S0959-8049(96)00510-2 10.1111/j.1742-7843.2006.pto_485.x 10.1158/0008-5472.CAN-03-2770 10.1146/annurev.med.53.082901.103929 10.1016/S0092-8674(00)81683-9 10.1248/bpb.27.1769 10.1158/1535-7163.MCT-07-0147 10.2174/092986709789104993 10.1016/S0304-3835(02)00025-3 10.1002/ijc.21893 10.3748/wjg.v16.i18.2235 10.1016/j.canlet.2007.12.004 10.1248/bpb.27.998 10.1007/s10541-005-0105-4 10.1016/j.lfs.2005.06.046 10.1007/s00109-008-0398-z 10.1093/jnci/djj234 10.1002/bit.260110607 10.1136/jcp.54.12.927 10.1093/jnci/86.20.1517 10.1054/drup.1999.0094 10.7326/0003-4819-91-5-710 10.1073/pnas.88.10.4328 10.1016/j.canlet.2007.06.014 10.3748/wjg.14.1491 10.1016/j.jhep.2006.08.012 10.1038/sj.bjc.6603127 10.1016/j.canlet.2010.12.015 10.1016/S0024-3205(98)00618-3 10.1002/hep.510260413 10.1016/j.biopha.2008.07.089 10.1055/s-2006-951748 10.1002/hep.21330 10.1159/000077991 10.1016/j.tox.2008.11.014 10.1021/bi001603q 10.1038/ng.2806 10.1186/1472-6750-5-12 10.1093/jnci/92.16.1295 10.1159/000151541 10.1038/sj.onc.1206945 |
ContentType | Journal Article |
Copyright | Hahnvajanawong et al.; licensee BioMed Central Ltd. 2014 2014 Hahnvajanawong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
Copyright_xml | – notice: Hahnvajanawong et al.; licensee BioMed Central Ltd. 2014 – notice: 2014 Hahnvajanawong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
DBID | C6C AAYXX CITATION NPM 3V. 7TM 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/1475-2867-14-68 |
DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef PubMed ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
Database_xml | – sequence: 1 dbid: C6C name: SpringerOpen Free (Free internet resource, activated by CARLI) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1475-2867 |
EndPage | 68 |
ExternalDocumentID | PMC4392878 oai_biomedcentral_com_1475_2867_14_68 3492902981 25866479 10_1186_1475_2867_14_68 |
Genre | Journal Article |
GroupedDBID | --- 0R~ 29B 2WC 4.4 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR ISR ITC KQ8 M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PUEGO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M 2VQ 88E 8R4 8R5 AAYXX ALIPV C1A CITATION IPNFZ LGEZI LOTEE M1P NADUK NXXTH PSQYO RIG NPM 3V. 7TM 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 -56 -5G -A0 -BR ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 FRP 5PM |
ID | FETCH-LOGICAL-b622t-e907d0504a19c62f022dc7094387456f02574050d6e4849fad7191c2d69ae0f43 |
IEDL.DBID | 7X7 |
ISSN | 1475-2867 |
IngestDate | Thu Aug 21 13:37:21 EDT 2025 Wed May 22 07:11:58 EDT 2024 Fri Sep 05 04:09:15 EDT 2025 Sun Jun 29 16:58:59 EDT 2025 Thu Apr 03 07:06:22 EDT 2025 Thu Apr 24 23:02:53 EDT 2025 Tue Jul 01 02:41:37 EDT 2025 Sat Sep 06 07:29:31 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Isomorellin Human cholangiocarcinoma cell lines Synergistic effect Forbesione Doxorubicin Apoptosis |
Language | English |
License | This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b622t-e907d0504a19c62f022dc7094387456f02574050d6e4849fad7191c2d69ae0f43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.proquest.com/docview/1622956880?pq-origsite=%requestingapplication% |
PMID | 25866479 |
PQID | 1622956880 |
PQPubID | 42567 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4392878 biomedcentral_primary_oai_biomedcentral_com_1475_2867_14_68 proquest_miscellaneous_1673078525 proquest_journals_1622956880 pubmed_primary_25866479 crossref_citationtrail_10_1186_1475_2867_14_68 crossref_primary_10_1186_1475_2867_14_68 springer_journals_10_1186_1475_2867_14_68 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-10-24 |
PublicationDateYYYYMMDD | 2014-10-24 |
PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-24 day: 24 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Cancer cell international |
PublicationTitleAbbrev | Cancer Cell Int |
PublicationTitleAlternate | Cancer Cell Int |
PublicationYear | 2014 |
Publisher | BioMed Central BioMed Central Ltd |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
References | 10.1186/1475-2867-14-68-B13 10.1186/1475-2867-14-68-B35 10.1186/1475-2867-14-68-B12 10.1186/1475-2867-14-68-B56 10.1186/1475-2867-14-68-B11 10.1186/1475-2867-14-68-B33 10.1186/1475-2867-14-68-B55 10.1186/1475-2867-14-68-B10 10.1186/1475-2867-14-68-B31 10.1186/1475-2867-14-68-B53 10.1186/1475-2867-14-68-B52 10.1186/1475-2867-14-68-B51 10.1186/1475-2867-14-68-B50 10.1186/1475-2867-14-68-B19 10.1186/1475-2867-14-68-B18 10.1186/1475-2867-14-68-B17 10.1186/1475-2867-14-68-B39 10.1186/1475-2867-14-68-B16 10.1186/1475-2867-14-68-B15 10.1186/1475-2867-14-68-B37 10.1186/1475-2867-14-68-B36 10.1186/1475-2867-14-68-B3 10.1186/1475-2867-14-68-B2 10.1186/1475-2867-14-68-B1 10.1186/1475-2867-14-68-B24 10.1186/1475-2867-14-68-B46 10.1186/1475-2867-14-68-B23 10.1186/1475-2867-14-68-B44 10.1186/1475-2867-14-68-B21 10.1186/1475-2867-14-68-B43 10.1186/1475-2867-14-68-B42 10.1186/1475-2867-14-68-B9 10.1186/1475-2867-14-68-B29 10.1186/1475-2867-14-68-B8 10.1186/1475-2867-14-68-B7 10.1186/1475-2867-14-68-B27 10.1186/1475-2867-14-68-B49 10.1186/1475-2867-14-68-B6 10.1186/1475-2867-14-68-B26 10.1186/1475-2867-14-68-B5 10.1186/1475-2867-14-68-B25 10.1186/1475-2867-14-68-B47 17117343 - Planta Med. 2007 Jan;73(1):33-40 18248784 - Cancer Lett. 2008 Apr 18;262(2):214-22 1903539 - Proc Natl Acad Sci U S A. 1991 May 15;88(10):4328-32 11773296 - J Natl Cancer Inst Monogr. 2001;(30):72-9 10647931 - Cell. 2000 Jan 7;100(1):57-70 15958484 - Ann Oncol. 2005;16 Suppl 2:ii93-6 10075109 - Life Sci. 1999;64(9):763-74 9721092 - Science. 1998 Aug 28;281(5381):1309-12 18330936 - World J Gastroenterol. 2008 Mar 14;14(10):1491-7 15807663 - Biochemistry (Mosc). 2005 Feb;70(2):231-9 12429642 - Clin Cancer Res. 2002 Nov;8(11):3512-9 20458760 - World J Gastroenterol. 2010 May 14;16(18):2235-43 22972485 - Biol Pharm Bull. 2012;35(11):1914-25 17012222 - Carcinogenesis. 2007 Mar;28(3):632-8 16918721 - Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):178-84 15516720 - Biol Pharm Bull. 2004 Nov;27(11):1769-74 19084572 - Toxicology. 2009 Feb 4;256(1-2):135-40 18804944 - Biomed Pharmacother. 2008 Nov;62(9):622-9 16570287 - Int J Cancer. 2006 Sep 1;119(5):1067-72 18070617 - Biochem Pharmacol. 2008 Mar 1;75(5):1083-92 11818492 - Annu Rev Med. 2002;53:615-27 17693016 - Cancer Lett. 2007 Oct 28;256(2):259-66 15150106 - Cancer Res. 2004 May 15;64(10):3517-24 15948244 - World J Gastroenterol. 2005 Jun 14;11(22):3392-7 17203872 - Acta Pol Pharm. 2006 Jul-Aug;63(4):321-4 11170436 - Biochemistry. 2001 Jan 30;40(4):1117-23 9328309 - Hepatology. 1997 Oct;26(4):884-90 496103 - Ann Intern Med. 1979 Nov;91(5):710-7 10973057 - Trends Biochem Sci. 2000 Sep;25(9):434-40 17876042 - Mol Cancer Ther. 2007 Sep;6(9):2429-40 21216092 - Cancer Lett. 2011 Feb 28;301(2):221-8 17069924 - J Hepatol. 2007 Feb;46(2):222-9 9274436 - Eur J Cancer. 1997 Apr;33(4):566-74 11504498 - Drug Resist Updat. 1999 Aug;2(4):271-273 10944550 - J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302 15884115 - World J Gastroenterol. 2005 May 14;11(18):2748-53 5365804 - Biotechnol Bioeng. 1969 Nov;11(6):1101-10 24185513 - Nat Genet. 2013 Dec;45(12 ):1474-8 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 7932806 - J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8 15885144 - BMC Biotechnol. 2005 May 10;5:12 19747141 - Curr Med Chem. 2009;16(28):3775-96 18714155 - Chemotherapy. 2008;54(5):343-51 17006947 - Hepatology. 2006 Oct;44(4):1025-38 18777017 - J Mol Med (Berl). 2008 Dec;86(12 ):1367-77 11983155 - Cell. 2002 Apr;109 Suppl:S81-96 15256729 - Biol Pharm Bull. 2004 Jul;27(7):998-1003 14576849 - Oncogene. 2003 Oct 20;22(47):7414-30 19243472 - J Cell Mol Med. 2010 Mar;14(3):687-98 16257012 - Life Sci. 2006 Feb 9;78(11):1238-45 11729212 - J Clin Pathol. 2001 Dec;54(12):927-32 12430184 - Cancer Lett. 2002 Jul 8;181(1):95-107 15218306 - Oncology. 2004;66(3):167-79 |
References_xml | – ident: 10.1186/1475-2867-14-68-B33 doi: 10.1016/S0968-0004(00)01617-0 – ident: 10.1186/1475-2867-14-68-B5 doi: 10.1016/S0959-8049(96)00510-2 – ident: 10.1186/1475-2867-14-68-B27 doi: 10.1111/j.1742-7843.2006.pto_485.x – ident: 10.1186/1475-2867-14-68-B10 doi: 10.1158/0008-5472.CAN-03-2770 – ident: 10.1186/1475-2867-14-68-B43 doi: 10.1146/annurev.med.53.082901.103929 – ident: 10.1186/1475-2867-14-68-B7 doi: 10.1016/S0092-8674(00)81683-9 – ident: 10.1186/1475-2867-14-68-B37 doi: 10.1248/bpb.27.1769 – ident: 10.1186/1475-2867-14-68-B24 doi: 10.1158/1535-7163.MCT-07-0147 – ident: 10.1186/1475-2867-14-68-B18 doi: 10.2174/092986709789104993 – ident: 10.1186/1475-2867-14-68-B39 doi: 10.1016/S0304-3835(02)00025-3 – ident: 10.1186/1475-2867-14-68-B12 doi: 10.1002/ijc.21893 – ident: 10.1186/1475-2867-14-68-B29 doi: 10.3748/wjg.v16.i18.2235 – ident: 10.1186/1475-2867-14-68-B16 doi: 10.1016/j.canlet.2007.12.004 – ident: 10.1186/1475-2867-14-68-B19 doi: 10.1248/bpb.27.998 – ident: 10.1186/1475-2867-14-68-B46 doi: 10.1007/s10541-005-0105-4 – ident: 10.1186/1475-2867-14-68-B21 doi: 10.1016/j.lfs.2005.06.046 – ident: 10.1186/1475-2867-14-68-B23 doi: 10.1007/s00109-008-0398-z – ident: 10.1186/1475-2867-14-68-B1 doi: 10.1093/jnci/djj234 – ident: 10.1186/1475-2867-14-68-B42 doi: 10.1002/bit.260110607 – ident: 10.1186/1475-2867-14-68-B8 doi: 10.1136/jcp.54.12.927 – ident: 10.1186/1475-2867-14-68-B31 doi: 10.1093/jnci/86.20.1517 – ident: 10.1186/1475-2867-14-68-B49 doi: 10.1054/drup.1999.0094 – ident: 10.1186/1475-2867-14-68-B6 doi: 10.7326/0003-4819-91-5-710 – ident: 10.1186/1475-2867-14-68-B25 doi: 10.1073/pnas.88.10.4328 – ident: 10.1186/1475-2867-14-68-B26 doi: 10.1016/j.canlet.2007.06.014 – ident: 10.1186/1475-2867-14-68-B55 doi: 10.3748/wjg.14.1491 – ident: 10.1186/1475-2867-14-68-B50 doi: 10.1016/j.jhep.2006.08.012 – ident: 10.1186/1475-2867-14-68-B2 doi: 10.1038/sj.bjc.6603127 – ident: 10.1186/1475-2867-14-68-B35 doi: 10.1016/j.canlet.2010.12.015 – ident: 10.1186/1475-2867-14-68-B15 doi: 10.1016/S0024-3205(98)00618-3 – ident: 10.1186/1475-2867-14-68-B9 doi: 10.1002/hep.510260413 – ident: 10.1186/1475-2867-14-68-B51 doi: 10.1016/j.biopha.2008.07.089 – ident: 10.1186/1475-2867-14-68-B36 doi: 10.1055/s-2006-951748 – ident: 10.1186/1475-2867-14-68-B52 doi: 10.1002/hep.21330 – ident: 10.1186/1475-2867-14-68-B3 doi: 10.1159/000077991 – ident: 10.1186/1475-2867-14-68-B17 doi: 10.1016/j.tox.2008.11.014 – ident: 10.1186/1475-2867-14-68-B47 doi: 10.1021/bi001603q – ident: 10.1186/1475-2867-14-68-B53 doi: 10.1038/ng.2806 – ident: 10.1186/1475-2867-14-68-B56 doi: 10.1186/1472-6750-5-12 – ident: 10.1186/1475-2867-14-68-B13 doi: 10.1093/jnci/92.16.1295 – ident: 10.1186/1475-2867-14-68-B11 doi: 10.1159/000151541 – ident: 10.1186/1475-2867-14-68-B44 doi: 10.1038/sj.onc.1206945 – reference: 16918721 - Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):178-84 – reference: 11729212 - J Clin Pathol. 2001 Dec;54(12):927-32 – reference: 1903539 - Proc Natl Acad Sci U S A. 1991 May 15;88(10):4328-32 – reference: 16736026 - Br J Cancer. 2006 Jun 5;94(11):1751-8 – reference: 7932806 - J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 – reference: 14576849 - Oncogene. 2003 Oct 20;22(47):7414-30 – reference: 15884115 - World J Gastroenterol. 2005 May 14;11(18):2748-53 – reference: 12429642 - Clin Cancer Res. 2002 Nov;8(11):3512-9 – reference: 16788161 - J Natl Cancer Inst. 2006 Jun 21;98(12):873-5 – reference: 10973057 - Trends Biochem Sci. 2000 Sep;25(9):434-40 – reference: 17117343 - Planta Med. 2007 Jan;73(1):33-40 – reference: 16257012 - Life Sci. 2006 Feb 9;78(11):1238-45 – reference: 17069924 - J Hepatol. 2007 Feb;46(2):222-9 – reference: 11818492 - Annu Rev Med. 2002;53:615-27 – reference: 15218306 - Oncology. 2004;66(3):167-79 – reference: 18804944 - Biomed Pharmacother. 2008 Nov;62(9):622-9 – reference: 5365804 - Biotechnol Bioeng. 1969 Nov;11(6):1101-10 – reference: 15885144 - BMC Biotechnol. 2005 May 10;5:12 – reference: 21216092 - Cancer Lett. 2011 Feb 28;301(2):221-8 – reference: 22972485 - Biol Pharm Bull. 2012;35(11):1914-25 – reference: 19747141 - Curr Med Chem. 2009;16(28):3775-96 – reference: 15256729 - Biol Pharm Bull. 2004 Jul;27(7):998-1003 – reference: 17203872 - Acta Pol Pharm. 2006 Jul-Aug;63(4):321-4 – reference: 17693016 - Cancer Lett. 2007 Oct 28;256(2):259-66 – reference: 11504498 - Drug Resist Updat. 1999 Aug;2(4):271-273 – reference: 18330936 - World J Gastroenterol. 2008 Mar 14;14(10):1491-7 – reference: 12430184 - Cancer Lett. 2002 Jul 8;181(1):95-107 – reference: 15516720 - Biol Pharm Bull. 2004 Nov;27(11):1769-74 – reference: 15150106 - Cancer Res. 2004 May 15;64(10):3517-24 – reference: 20458760 - World J Gastroenterol. 2010 May 14;16(18):2235-43 – reference: 10647931 - Cell. 2000 Jan 7;100(1):57-70 – reference: 19084572 - Toxicology. 2009 Feb 4;256(1-2):135-40 – reference: 15948244 - World J Gastroenterol. 2005 Jun 14;11(22):3392-7 – reference: 496103 - Ann Intern Med. 1979 Nov;91(5):710-7 – reference: 10075109 - Life Sci. 1999;64(9):763-74 – reference: 18248784 - Cancer Lett. 2008 Apr 18;262(2):214-22 – reference: 11773296 - J Natl Cancer Inst Monogr. 2001;(30):72-9 – reference: 17012222 - Carcinogenesis. 2007 Mar;28(3):632-8 – reference: 18070617 - Biochem Pharmacol. 2008 Mar 1;75(5):1083-92 – reference: 18777017 - J Mol Med (Berl). 2008 Dec;86(12 ):1367-77 – reference: 11170436 - Biochemistry. 2001 Jan 30;40(4):1117-23 – reference: 9274436 - Eur J Cancer. 1997 Apr;33(4):566-74 – reference: 15807663 - Biochemistry (Mosc). 2005 Feb;70(2):231-9 – reference: 11983155 - Cell. 2002 Apr;109 Suppl:S81-96 – reference: 10944550 - J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302 – reference: 15958484 - Ann Oncol. 2005;16 Suppl 2:ii93-6 – reference: 17006947 - Hepatology. 2006 Oct;44(4):1025-38 – reference: 18714155 - Chemotherapy. 2008;54(5):343-51 – reference: 19243472 - J Cell Mol Med. 2010 Mar;14(3):687-98 – reference: 17876042 - Mol Cancer Ther. 2007 Sep;6(9):2429-40 – reference: 9328309 - Hepatology. 1997 Oct;26(4):884-90 – reference: 24185513 - Nat Genet. 2013 Dec;45(12 ):1474-8 – reference: 16570287 - Int J Cancer. 2006 Sep 1;119(5):1067-72 – reference: 9721092 - Science. 1998 Aug 28;281(5381):1309-12 |
SSID | ssj0017860 |
Score | 2.1151295 |
Snippet | Background
Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural... Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural compounds... Doc number: 68 Abstract Background: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic... BACKGROUND: Chemotherapy for advanced cholangiocarcinoma (CCA) is largely ineffective, but innovative combinations of chemotherapeutic agents and natural... |
SourceID | pubmedcentral biomedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 68 |
SubjectTerms | Biomedical and Life Sciences Biomedicine Cancer Research Cell Biology Cell cycle Medical research Mortality Primary Research Studies |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZpQqGX0qQvt0lRoYf24NRW9SSEEEpCCKSXdiE3YVt2s7C1tutdyN760zsj25s6u83NiyX0mtF830r-hpAPKJGFSBtJDhAUgftgmVexEhXYjykqHnQKrr7JixG_vBbXd-mAuglsNlI7zCc1mk0Ob38vT8Dhj4PDa_k55UrETIPHpzyW-hHZgbAkkYld8bsjBaVl0mn7bKh073v3yTBMrWHP9SuU985RQ3g6f0aedriSnraGsEu2ynqPPG4zTS6fkz_fl_iRX1Blpt0dDuorOm483rRFYW6a1Y4ChMVMAb4uKf5DS52_9bNFjsfv1EORqZ_OfTNuKFD5VncWnmhI9EfDXNY_xxAdZ1De_8ooHgtQBLLNCzI6P_vx9SLuki_EuWRsHpfAml0iEp6lppCsgljvCoX3EFEgX8JvoQDsJU6WXHNTZU4B9SuYkyYrk4p_eUm2a-jtawJtOZdmLOF5YYCumlyniXHGAfLSIpNFRI4Gc2-nrdCGRenr4RvwQosrZ3Hl4MlKHZHDfqVs0emaY3qNiQ38Rsv1Ch9XFfqW_lt0v19625umTSWmQJew8UXk_eo1eCXOaVaXfoFlYOdUWjARkVetpazaYkJLyZWJiBrY0GDYwzf1-CYofwN6BIYL3frUW9s_3do8hDcPD-EteQIQkGM0ZnyfbM9ni_IAYNY8fxfc5y-MPSaT priority: 102 providerName: Scholars Portal – databaseName: SpringerOpen Free (Free internet resource, activated by CARLI) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZpQqGX0iZ9OI-iQg_pwa2tSCOJnkJoCIHk0gZyE7Zltwuptax3obnlp2dG9i5xNj30ZqMRki2N5huN9A1jn4gii5A2OTnooChaB-uySbVqcP7YqpGRp-DiEs6u5Pm1uh5IkuguzMP4fW7gay61SoVBbc5lCuYZ21L5EcSoLJyswgXaQDbw9jxR6dFd9puxCVrDlevHIx_FSKPpOX3FXg6YkR_3g_yabdTtNnveZ5G83WF3P27pAl9kXObD-QweGj7pAp2iJdJtXrSeIzylLAChrTntvnIf_obZoqTQOg8oMg3TeegmHUc3veeUxScek_jx6AK3vyZo-WYoH_4UnLb8OYHU7g27Ov3-8-QsHRIrpCUIMU9r9Ih9pjJZ5LYC0aAd95WmM4ZEfg_4rjQCucxDLY20TeE1unWV8GCLOmvk0Vu22WJv3zNsy_u8EJksK4uuqC1NnllvPaIqowqoEvZt9O_dtCfRcERrPS5BDXM0co5GDp8cmIR9WY6UqwbOckqdceOi72JgvcLhqsKypX-K7i-H3g1627kcKL054KKWsI-rYtQ4-qdFW4cFyeCqqI0SKmHv-pmyaksoAyC1TZgezaHRZ49L2snvyOqNyBC9V-zW5-Vse9Ctpz9h9z9k99gLxHqSzK6Q-2xzPlvUB4in5uWHqEv3Bh8bcA priority: 102 providerName: Springer Nature |
Title | Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines |
URI | https://link.springer.com/article/10.1186/1475-2867-14-68 https://www.ncbi.nlm.nih.gov/pubmed/25866479 https://www.proquest.com/docview/1622956880 https://www.proquest.com/docview/1673078525 http://dx.doi.org/10.1186/1475-2867-14-68 https://pubmed.ncbi.nlm.nih.gov/PMC4392878 |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB-0RfBF_DZajxV80IfYJO5X8EHs0VKEFqkWDl-WJJvUg5o9L3dg3_zTndlsTuOpLyFhN-zHzM7H7uxvAJ4TRBZZ2uTkoIMiSA7WZRMr0SD_5FXDPU7Byak8PufvZ2IWNty6EFY5yEQvqK2raI98P5WUeFoiu71dfIspaxSdroYUGtdh10OXIT-r2cbhSpWWSYDzSbXcT7kScaZRMqQ8JmzV0RX3y7Fm2jI3t6Mm_zg69Rrp6DbcCqYke9fT_g5cq9u7cKNPLnl1D358vKJ7fR6ImYWwDeYaNu8cBdcSFjcrWsvQaqXkAK6tGW3KMuu-u-W6pBN35rDKwi1Wrpt3DL33HmoW35jP7ce8Z9xezFEhLrG--1owOglgZLt29-H86PDT9DgO-RbiEid3FdfoKNtEJLxI80pmDap3WykKPSRMfInfQqF9l1hZc83zprAKvb0qszIv6qThrx_ATou9fQTYlrVpkSW8rHL0UPNSp0luc4vGlhaFrCJ4M5p7s-ixNQyhXY9LkAkMUc4Q5fDNSB3Bq4FSpgpQ5pRR49J4l0bL7R9ebH4YWvpn1b2B9CYs5878Yr4Inm2KcSHSnBZt7dZUB4Wl0iITETzsOWXTVia0lFzlEagRD42GPS5p51882DcajOjUYrdeDtz2W7f-PoTH_x_CE7iJVh8nBZzxPdhZLdf1U7SsVuXEL58J7B4cnn44w6-pnE78LgU-T7jG59nB559lkymF |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG_SFjASSHAITVLbcYQQ4tFqS9sVglbqzSRxQiO18bLZVdkbv4jfyEweC2GBW2-J7MR2ZjyPzPgbgMcEkUWWNjk56KAIkoNZkruhyJF_ojTnNU7BwUgOj_j7Y3G8Aj-6szCUVtnJxFpQG5vSP_JNX1LhaYns9mr81aWqURRd7UpoNGyxl83P0WWrXu6-Q_o-CYKd7cO3Q7etKuAm-Iqpm6E7aDzh8diPUhnkqMRMGlKCHSG_S7wXIVoxnpEZVzzKYxOiT5MGRkZx5uV8C997CVY5nWgdwOqb7dGHj4u4Raik1wII-Upu-jwUbqBQFvncJTTX3qH6074uXDJwl_M0_wjW1jpw5zpca41X9rrhthuwkpU34XJTznJ-C75_mtNJwhr6mbWJIszmrKgspfMS-jeLS8PQTqZyBLbMGP0GZsZ-s5NZQjF-ZrHL2I6ntioqVpSmAbfFK1ZXE2S1L15-KVAFT7C_PYsZxR4YWcvVbTi6EFrcgUGJs70HOJYxfhx4PEkj9ImjRPleZCKD5p0SsUwdeNH79nrcoHlowtfutyDbaaKcJsrhlZbKgecdpXTagqdTDY9TXTtRSi4_8HTxQDfSP7tudKTXrQCp9C92d-DRohm3Pn3TuMzsjPqgeA6VCIQDdxtOWYwVCCUlDyMHwh4P9ZbdbymLkxpeHE1UdKNxWs86bvttWn9fwtr_l_AQrgwPD_b1_u5obx2uos3JSf0HfAMG08ksu4923TR50G4mBp8vev_-BImJYAU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9RADLagCMQFlVcJFBgkDnAITYZ5ilNVWJVXhQSVehslmQRWKpnVJivRW386dh6rplsO3LIaj2YS22N77fkM8JIgssjTpiAHAxRJ52CZV7GWFcqPLSrR4RR8PVKHx-LTiTwZanOasdp9TEn2dxoIpalu9xa-6lXcqL1UaBlzgzqeiliZ63BDkN2jXK06WCcRtFHJgOZzxaRLN9xPp4Zpw9vcLJq8lDntDNJsG-4MniTb71l_F66V9T242feWPLsP59_P6Fpfh8PMhqoNFio2bwLV1hIUN8tqz9Bppd4AoS4Z_SfLfPgTlqucEu4sIMkiLNrQzBuGwXuPNItPrGvtx7rAuP45R3u4RPrwO2OUCGDkujYP4Hj24cfBYTy0W4hzxXkblxgn-0QmIkttoXiF1t0XmioPCRJf4W-p0b1LvCqFEbbKvMZgr-Be2axMKvH2IWzVuNtHgGt5n2Y8EXlhMUC1uUkT661HX8vITBURvJt8e7fooTUcgV1PR1AEHHHOEefwySkTwZuRU64YkMypocap6yIaozYnvFpPGFf6J-nuyHo3aHPjUkVNzxUedRG8WA-jHtI3zeoyrIgGz0ptJJcR7PSSsl6LS6OU0DYCPZGhyWtPR-r5rw7rG_1FjGlxW69Habuwratf4fF_0D6HW9_ez9yXj0efn8BtdAYF2WUudmGrXa7Kp-hwtfmzTq3-AllSJqQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synergistic+effects+of+isomorellin+and+forbesione+with+doxorubicin+on+apoptosis+induction+in+human+cholangiocarcinoma+cell+lines&rft.jtitle=Cancer+cell+international&rft.au=Hahnvajanawong%2C+Chariya&rft.au=Wattanawongdon%2C+Wareeporn&rft.au=Chomvarin%2C+Chariya&rft.au=Anantachoke%2C+Natthinee&rft.date=2014-10-24&rft.pub=BioMed+Central&rft.eissn=1475-2867&rft.volume=14&rft_id=info:doi/10.1186%2F1475-2867-14-68&rft.externalDocID=3492902981 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon |